PAVmed
PAVM
20 hedge funds and large institutions have $5.56M invested in PAVmed in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
42,152% more capital inflows, than outflows
Capital inflows: $3M | Capital outflows: $7.11K
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4.85% more ownership
Funds ownership: 8.02% → 12.87% (+4.8%)
0% more funds holding
Funds holding: 20 → 20 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$2.19M |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$394K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$176K |
| 4 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$143K |
| 5 |
BlackRock
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
-$6.31K |
| 2 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
-$619 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$127 |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$20 |
| 5 |
Morgan Stanley
New York
|
-$14 |
PAVM Hedge Fund Activity: Q2 2026 in Review
20 of the 8,372 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q2 2026, worth a combined $5.56M — up 7% from $5.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PAVM positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 3 trimmed.
The largest buyer was First Manhattan, adding an estimated $2.19M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $6.31K sold.
- 20 institutional investors held PAVmed (PAVM) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $5.56M of PAVmed stock for Q2 2026, up 7% quarter-over-quarter.
- 5 funds opened new PAVmed positions in Q2 2026 and 4 closed out, a net change of +1 holder.
- The largest PAVmed buyer in Q2 2026 was First Manhattan, an estimated $2.19M added.
- The largest PAVmed seller in Q2 2026 was Tower Research Capital (TRC), an estimated $6.31K sold.
Based on aggregated 13F filings for Q2 2026.